Model 1 (including LDL-C, IL-17, and Th17) outperformed Model 2 in predicting RA-obstructive CAD risk (AUC = 0.97 vs. AUC = 0.88), validating the importance of immune biomarkers in RA-obstructive CAD risk assessment. This evidence concerns the gene IL17A and rheumatoid arthritis.